Brent L. Saunders net worth and biography

Brent Saunders Biography and Net Worth

Chairman of Allergan

Mr. Saunders is Chairman, President and Chief Executive Officer of Allergan and has served in the role of President and Chief Executive Officer since July 2014 and of Chairman since October 2016, having previously served as Chief Executive Officer and President, and as director, of Forest Laboratories, Inc. , prior to its acquisition by Allergan.

Prior to that, he served as Chief Executive Officer of Bausch + Lomb Incorporated, a leading global eye health company, serving in this capacity from March 2010 until August 2013. Mr. Saunders also held a number of leadership positions at Schering-Plough, including the position of President of Global Consumer Health Care and was named head of integration for the company’s merger with Merck & Co. and for Schering-Plough’s acquisition of Organon BioSciences. Before joining Schering-Plough, Mr. Saunders was a Partner and Head of Compliance Business Advisory at PricewaterhouseCoopers LLP. Prior to that, he was Chief Risk Officer at Coventry Health Care and Senior Vice President, Compliance, Legal and Regulatory at Home Care Corporation of America. Mr. Saunders began his career as Chief Compliance Officer for the Thomas Jefferson University Health System. Mr. Saunders serves on the Board of Directors of Cisco Systems, Inc. and The Allergan Foundation, and is a member of the Business Council, the Business Roundtable and PhRMA.

What is Brent L. Saunders' net worth?: The estimated net worth of Brent L. Saunders is at least $138.81 million as of May 22nd, 2025. Mr. Saunders owns 719,156 shares of Allergan stock worth more than $138,811,491 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Saunders may own. Learn More about Brent L. Saunders' net worth.
How old is Brent L. Saunders?: Mr. Saunders is currently 49 years old. There are 4 older executives and no younger executives at Allergan. Learn More on Brent L. Saunders' age.
How do I contact Brent L. Saunders?: The corporate mailing address for Mr. Saunders and other Allergan executives is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. Allergan can also be reached via phone at 862-261-7000 and via email at [email protected]. Learn More on Brent L. Saunders' contact information.
Has Brent L. Saunders been buying or selling shares of Allergan?: Brent L. Saunders has not been actively trading shares of Allergan during the last quarter. Most recently, on Thursday, March 7th, Brent L. Saunders bought 1,760 shares of Allergan stock. The stock was acquired at an average cost of $143.67 per share, with a total value of $252,859.20. Learn More on Brent L. Saunders' trading history.
Who are Allergan's active insiders?: Allergan's insider roster includes Brent Saunders (Chairman), Brenton Saunders (Chairman & CEO), and Matthew Walsh (Exec. VP & CFO ). Learn More on Allergan's active insiders.

Brent L. Saunders Insider Trading History at Allergan

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2019	Buy	1,760	$143.67	$252,859.20
3/8/2018	Buy	3,300	$152.53	$503,349.00
12/6/2017	Buy	4,600	$164.74	$757,804.00
11/21/2016	Buy	5,250	$189.13	$992,932.50
8/21/2015	Buy	1,000	$301.94	$301,940.00	132,862

Brent L. Saunders Buying and Selling Activity at Allergan

Allergan Company Overview

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Today's Range

Now: $193.02

$191.64

$193.38

50 Day Range

MA: $190.89

$184.04

$193.89

2 Week Range

Now: $193.02

$114.27

$202.21

Volume

12,442,653 shs

Average Volume

4,008,576 shs

Market Capitalization

$63.50 billion

P/E Ratio

N/A

Dividend Yield

1.53%

Beta

1.2